CAPTRUST Financial Advisors
CTMX icon

CAPTRUST Financial Advisors’s CytomX Therapeutics CTMX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-429
Closed -$1K – 2497
2022
Q2 		$1K Sell
429
-735
-63% -$1.41K ﹤0.01% 4655
2022
Q1 		$3K Buy
1,164
+164
+16% +$630 ﹤0.01% 4344
2021
Q4 		$4K Hold
1,000
– – ﹤0.01% 4168
2021
Q3 		$5K Hold
1,000
– – ﹤0.01% 3936
2021
Q2 		$6K Buy
1,000
+300
+43% +$2.34K ﹤0.01% 3772
2021
Q1 		$5K Buy
+700
New +$5.54K ﹤0.01% 3720

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

CAPTRUST Financial Advisors's CTMX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of CytomX Therapeutics (CTMX) in Q3 2022, closing a stake of 429 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in CTMX in Q1 2021 and held it in 6 quarters. The position peaked at $6K in Q2 2021. 84 funds tracked by Wall St. Rank hold CTMX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining CytomX Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 429 CytomX Therapeutics shares in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in CytomX Therapeutics in Q1 2021 and held it in 6 quarters.
  • CAPTRUST Financial Advisors's CytomX Therapeutics position peaked at $6K in Q2 2021.
  • 84 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.